GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

NCT02983604 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Estrogen Receptor Positive HER2- Breast Cancer

Interventions

DRUG: GS-5829
DRUG: Exemestane
DRUG: Fulvestrant

Sponsor

Gilead Sciences